Patents by Inventor Christopher T. Baker

Christopher T. Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of aspartyl protease
    Patent number: 7919523
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 5, 2011
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • Inhibitors of aspartyl protease
    Publication number: 20090042973
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: July 2, 2008
    Publication date: February 12, 2009
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • Inhibitors of aspartyl protease
    Patent number: 7442718
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: October 28, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R Hale, Christopher T Baker, Timothy A Stammers, Ronald G Sherrill, Andrew Spaltenstein, Eric S Furfine, Francois Maltais, Clarence W Andrews, III, John F Miller, Vicente Samano
  • Ion Channel Modulators
    Publication number: 20080242716
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.
    Type: Application
    Filed: March 7, 2005
    Publication date: October 2, 2008
    Inventors: Robert Zelle, Christopher T. Baker
  • Inhibitors of aspartyl protease
    Publication number: 20040127488
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: July 2, 2003
    Publication date: July 1, 2004
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, John Franklin Miller, Vicente Samano
  • Inhibitors of aspartyl protease
    Patent number: 6617350
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: September 9, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, François Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • Prodrugs of aspartyl protease inhibitors
    Publication number: 20030144217
    Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.
    Type: Application
    Filed: August 21, 2002
    Publication date: July 31, 2003
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Michael R. Hale, Christopher T. Baker, Andrew Spaltenstein, Eric S. Furfine, Istvan Kaldor, Wieslaw M. Kazmierski
  • Inhibitors of aspartyl protease
    Publication number: 20020198388
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: August 9, 2001
    Publication date: December 26, 2002
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald G. Sherrill, Andrew Spaltenstein, Eric S. Furfine, Francois Maltais, Clarence W. Andrews, John F. Miller, Vicente Samano
  • Prodrugs of aspartyl protease inhibitors
    Patent number: 6436989
    Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: August 20, 2002
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Michael R. Hale, Roger D. Tung, Christopher T. Baker, Andrew Spaltenstein
  • Inhibitors of aspartyl protease
    Patent number: 6319946
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: November 20, 2001
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • Tire tread
    Patent number: D436063
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: January 9, 2001
    Assignee: Bridgestone/Firestone Research, Inc.
    Inventor: Christopher T. Baker
  • Tire tread
    Patent number: D437264
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: February 6, 2001
    Assignee: Bridgestone/Firestone Research, Inc.
    Inventors: Timothy J. Lassan, Christopher T. Baker, Brian J. Queiser
  • Tire tread
    Patent number: D440529
    Type: Grant
    Filed: April 13, 1999
    Date of Patent: April 17, 2001
    Assignee: Bridgestone/Firestone Research, Inc.
    Inventors: Timothy J. Lassan, Christopher T. Baker, Brian J. Queiser
  • Tire tread
    Patent number: D448328
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: September 25, 2001
    Assignee: Bridgestone/Firestone Research, Inc.
    Inventors: Keith A. Dumigan, Christopher T. Baker, James G. Guspodin, Elizabeth M. Beutler
  • Tire tread
    Patent number: D449801
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: October 30, 2001
    Assignee: Bridgestone/Firestone Research, Inc.
    Inventors: Keith A. Dumigan, Christopher T. Baker, James G. Guspodin, Elizabeth M. Beutler
  • Tire tread
    Patent number: D450270
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: November 13, 2001
    Assignee: Bridgestone/Firestone Research, Inc.
    Inventor: Christopher T. Baker
  • Pneumatic tire tread and buttress
    Patent number: D459293
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: June 25, 2002
    Assignee: Kumho & Co, Inc
    Inventors: Christopher T Baker, Brian H Buckham, Andrew Reeves, Edward P Cercek, Rudy E Consolacion
  • Pneumatic tire and buttress
    Patent number: D467223
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: December 17, 2002
    Assignee: Kumho & Co., Inc
    Inventors: Christopher T Baker, Edward P Cercek, Gavin P Edwards
  • Automobile tire
    Patent number: D665727
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: August 21, 2012
    Assignee: Kumho Tire Co., Inc.
    Inventors: Jae Moon Lee, Uk Seo, Hae Dong Jung, Chang Jung Park, Jae Phil Park, Christopher T. Baker, Edward P. Cercek, Terry M. Edwards
  • Tire tread
    Patent number: D777653
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: January 31, 2017
    Inventors: Christopher T. Baker, Edward L. Montgomery, Christopher Kocaj, Ramendra Nath Majumdar, Xiaodong Wang